Ma Iulai 27, 2023, ua hoʻolaha ʻo Lilly ʻo ke aʻo ʻana ʻo Mount-3 o Tirzepatide no ka mālama ʻana i nā mea maʻi obese a me ke aʻo ʻana ʻo Mount-4 no ka mālama ʻana i ke kaumaha o ka poʻe maʻi obese i hiki i ka helu hope mua a me ka helu hope lua.ʻO kēia ke kolu a me ka hā o ka noiʻi holomua III i loaʻa e Tirzepatide ma hope o Mount-1 a me Mount-2.
ʻO SURMOUNT-3 (NCT04657016) he multicenter, randomized, double-blind, parallel, placebo-controlled trial e kākau inoa ana i ka huina o 806 mau mea komo i hoʻolālā ʻia e hōʻike i ke kūlana kiʻekiʻe o Tirzepatide ma luna o placebo e pili ana i ka pākēneka o ka loli kaumaha ma hope o ka randomization a me ka pakeneka o nā poʻe i lilo i ≥5% ma hope o ka randomization ma 72 wiki.
Ua hōʻike ʻia nā hopena haʻawina SURMOUNT-3 ua hālāwai ʻo Tirzepatide i nā hopena a pau, ʻo ia hoʻi ma hope o 72 mau pule o ka mālama ʻana, ua loaʻa i nā mea maʻi i ka hui Tirzepatide i kahi pākēneka kiʻekiʻe o ka poho kaumaha mai ka papa kuhikuhi i hoʻohālikelike ʻia me ka placebo, a me ka hapa nui o nā mea maʻi i ka hui Tirzepatide. ua loaʻa i kahi pākēneka o ka pohō kaumaha ma mua o 5%.Ua hōʻike ʻia nā ʻikepili kikoʻī i nā mea maʻi i mālama ʻia me Tirzepatide i ka awelika o 21.1% o ke kaumaha o ke kino i hoʻohālikelike ʻia me kahi placebo;Hoʻohui ʻia me ka manawa 12-week intervention, ua nalowale nā mea maʻi i mālama ʻia me Tirzepatide i ka awelika o 26.6 pakeneka o ko lākou kaumaha kino.Eia kekahi, 94.4% o nā mea maʻi i nalowale i ka ≥5% o ko lākou kaumaha ma ka hui Tirzepatide, ke hoʻohālikelike ʻia me 10.7% i ka hui placebo.
ʻO SURMOUNT-4 (NCT04660643) he multicenter, randomized, double-blind, parallel, placebo-controlled trial e kākau inoa ana i ka huina o 783 poʻe i hoʻolālā ʻia e hōʻike i ka ʻoi aku o Tirzepatide ma mua o ka placebo ma ka pākēneka hoʻololi kaumaha ma 88-wiki randomization.
Ua hōʻike ʻia nā hopena ma hope o ka manawa makapō ʻelua o 37 ~ 88 mau wiki, ua nalowale nā mea maʻi i ka hui Tirzepatide ma mua o ka hui placebo.Ma ke ʻano o ka palekana, ʻaʻole i nānā nā haʻawina SURMOUNT-3 a i ʻole SURMOUNT-4 i nā hōʻailona palekana hou.
Mai ka hoʻomaka ʻana o Novo Nordisk's blockbuster meaʻai lāʻau Semaglutide, i hui pū ʻia me Musk i kākoʻo ikaika ʻia, ua lilo ia i huahana kaulana kaulana o ka Internet a me ke aliʻi pohō kaumaha o kēia manawa.Nui ka noi o ka mākeke paona, a ʻelua wale nō GLP-1 mau lāʻau paona kaumaha i kēia manawa ma ka mākeke, ʻo Liraglutide a me Semaglutide, akā ʻo Liraglutide kahi hoʻomākaukau pōkole, ʻaʻole hiki ke hoʻokūkū me nā hoʻomākaukau lōʻihi e pili ana i ka hoʻokō ʻana i ka maʻi. , a ʻo ka honua pohō kaumaha o kēia manawa no Semaglutide.
ʻO ke aliʻi hoʻi o ka māla GLP-1, makemake ʻo Lilly i ka moana uliuli o ka mākeke hoʻemi kaumaha - no laila ua hoʻomaka ʻo Lilly i kahi hoʻokūkū a koho mua iā Tirzepatide e hopu i kahi ma ka mākeke pohō kaumaha.
ʻO Tirzepatide he GIPR / GLP-1R pālua agonist i kēlā me kēia pule, ʻo GIP (glucose-dependent insulin stimulating polypeptide) he lālā ʻē aʻe o ka ʻohana glucagon peptide, me ka hopena o ka hoʻoikaika ʻana i ka huna ʻana o ka insulin ma ke ʻano hilinaʻi insulin a me ka hoʻoulu ʻana i ka huna ʻana o ka glucagon i kahi hypoglycemic. mokuʻāina, hiki i ka GIPR/GLP-1R ʻelua agonist ke hoʻohua i ke kōpaʻa koko, ka pohō kaumaha a me nā hopena ʻē aʻe ma o ka hoʻoulu ʻana i nā ala GIP a me GLP-1 i lalo.Ua ʻae ʻia ʻo Tirzepatide e ka FDA ma 2022-5 (inoa kālepa: Mounjaro) no ka hoʻohana pū ʻana me ka meaʻai a me ka hoʻomaʻamaʻa e hoʻomaikaʻi i ka mana glycemic i nā pākeke me ka maʻi maʻi type 2.
Ka manawa hoʻouna: Sep-18-2023